Expedited Program Designation Requests — GLPI-103
| Field | Value |
|---|---|
| Document ID | DESIG-001 |
| Version | 1.0 |
| Status | Final (portfolio) |
| Compound | GLPI-103 (GLP-1 / Apelin [APJ] receptor dual agonist) |
| Sponsor | Virtual Biopharma Inc. |
| Standard(s) | FDA Expedited Programs Guidance (Fast Track · Breakthrough Therapy) · 21st Century Cures · EMA PRIME · MFDS expedited review |
| Confidentiality | Confidential |
[MOCK]Strategy and supporting rationale for expedited-program designation requests across FDA, EMA, and MFDS. Clinical evidence traces to the GLPI-103 program (CSR-201, CSR-301).
Change History
| Version | Date | Author | Summary |
|---|---|---|---|
| 1.0 | 2026-06-30 | Regulatory Affairs | Initial expedited-program strategy and requests |
1. Strategy Overview
GLPI-103 targets a serious chronic condition (T2DM with residual cardiometabolic risk) and has shown, in the pivotal study, superiority over a guideline-recommended therapy with a differentiated dual mechanism. The program pursues expedited pathways to accelerate access where the evidentiary criteria are met, while recognizing that designation does not lower the approval standard.
2. FDA — Fast Track Designation Request
- Criterion: drug for a serious condition with potential to address an unmet medical need.
- Rationale: despite GLP-1 therapies, many patients do not reach glycaemic targets and retain elevated cardiometabolic/heart-failure risk; GLPI-103's dual GLP-1/APJ mechanism targets this gap, with an oral option to improve access.
- Request: Fast Track designation for GLPI-103 in T2DM inadequately controlled on metformin; sought at/after the Pre-IND or EOP2 stage to enable rolling review and frequent FDA interaction.
3. FDA — Breakthrough Therapy Designation (BTD) Request
- Criterion: preliminary clinical evidence of substantial improvement over available therapy on a clinically significant endpoint.
- Rationale: the pivotal study demonstrated statistically significant superiority over oral semaglutide on HbA1c at Week 52 (IV −0.68%, Oral −0.34%; both p<0.001) with substantially greater weight reduction and higher responder rates (CSR-301; M2.7.3) — a basis for a substantial-improvement claim on a clinically significant endpoint.
- Request: BTD for the intravenous formulation (largest effect) in the target population; if granted, leverage intensive guidance and organizational commitment to expedite development.
4. EMA — PRIME (PRIority MEdicines) Eligibility
- Criterion: major therapeutic advantage / unmet need with compelling early clinical data.
- Rationale: the dual-mechanism cardiometabolic positioning and superiority data support a PRIME eligibility request, enabling early dialogue, a dedicated rapporteur, and accelerated-assessment potential at MAA.
5. MFDS (Korea) — Expedited Review
- Pursue MFDS expedited/priority review consistent with the global strategy, supported by the Korea-relevant pivotal population (Nemotron-Korea demographic basis; M1-KR).
6. Coordination and Risks
Designation requests are sequenced with the meeting plan (MTG-PREIND/EOP2/PRENDA) and the global submission timeline (PM-007). Risk: designations may be denied or withdrawn if confirmatory evidence is insufficient; the program is designed to succeed on the standard approval pathway regardless (PM-004 risk register).